wells_timothy

Kymab makes appointments and executive promotions

pharmafile | October 3, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Lisha Patel, Timothy Wells, jenny yip, kymab 

Following a $40 million investment from The Wellcome Trust and the Bill & Melinda Gates Foundation, biopharma UK firm Kymab has appointed Dr Timothy Wells (pictured) and Lisha Patel as non-executive directors.

Jenny Yip has also been taken on as a board observer, and amid the moves Dr Richard Davis is to stand down as non-executive director. 

Wells, a protein engineer by training, is currently chief scientific officer of the Medicines for Malaria Venture (MMV) in Geneva, and was previously senior executive VP of research at Serono.

Patel is head of direct private investments at the Wellcome Trust and Yip is senior program investment officer on the Program Related Investments (PRI) team at the Bill & Melinda Gates Foundation.

Dr Christian Grøndahl, who is the chief executive at Kymab, says: “Following the successful $40 million fundraising in May, we are delighted to strengthen our team and welcome Tim, Lisha and Jenny to the Kymab board.”

Kymab also announced two executive promotions: Dr Glenn Friedrich has been promoted to chief operating officer. Friedrich is a founder of the company and previously served as VP, then senior VP of Technology and Research Operations. 

Jasper Clube who joined the firm in 2010 has been promoted to senior VP of Intellectual Property and Chief Patent Counsel.

Related Content

Sanofi to acquire Kymab for $1.1bn

Sanofi is to acquire clinical-stage biopharmaceutical company Kymab for approximately $1.1 billion. In addition to …

kymab

Chinese investors push Kymab backing to $100 million

Kymab, the UK-based antibody biopharmaceutical group, announced that it has secured $100 million in funding. …

hiv-infected_h9_t-cell_-_credit_national_institutes_of_health-web

Kymab demonstrates promising research for HIV vaccine development

Cambridge-based antibodies-to-medicines company Kymab has announced publication of research testing the first step in the …

Latest content